Insider Selling: Mednax, Inc (MD) Insider Sells $154,740.00 in Stock

Mednax, Inc (NYSE:MD) insider John C. Pepia sold 3,000 shares of the stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Mednax, Inc (NYSE:MD) opened at $51.07 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax, Inc has a 1-year low of $40.56 and a 1-year high of $72.13. The firm has a market cap of $4,830.74, a P/E ratio of 15.77, a price-to-earnings-growth ratio of 1.66 and a beta of 0.40.

Mednax (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. During the same quarter last year, the company earned $1.09 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. sell-side analysts expect that Mednax, Inc will post 3.1 EPS for the current year.

Several research analysts have recently commented on MD shares. Jefferies Group reissued a “hold” rating and issued a $44.00 price objective on shares of Mednax in a research note on Friday, November 3rd. Piper Jaffray Companies started coverage on shares of Mednax in a research note on Wednesday. They issued an “overweight” rating and a $58.00 price objective for the company. KeyCorp raised shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research note on Sunday, September 17th. Citigroup lowered their price objective on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Finally, BMO Capital Markets started coverage on shares of Mednax in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $53.70.

Hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can increased its holdings in shares of Mednax by 0.7% in the 2nd quarter. Great West Life Assurance Co. Can now owns 77,858 shares of the company’s stock valued at $4,698,000 after acquiring an additional 510 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Mednax by 20.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after acquiring an additional 500 shares during the period. Sei Investments Co. increased its holdings in shares of Mednax by 3.1% in the 2nd quarter. Sei Investments Co. now owns 103,108 shares of the company’s stock valued at $6,224,000 after acquiring an additional 3,139 shares during the period. TD Asset Management Inc. increased its holdings in shares of Mednax by 1.2% in the 2nd quarter. TD Asset Management Inc. now owns 212,947 shares of the company’s stock valued at $12,856,000 after acquiring an additional 2,537 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Mednax by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 295,514 shares of the company’s stock valued at $17,841,000 after acquiring an additional 15,715 shares during the period. 98.48% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/12/15/insider-selling-mednax-inc-md-insider-sells-154740-00-in-stock.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply